News Focus
News Focus
icon url

X Master

12/09/22 10:19 AM

#546353 RE: LessIsMore #546346

Stupp needs to retire if he thinks trials for diseases with a death sentence need a control arm.
Bullish
Bullish
icon url

Fireman02360

12/09/22 11:06 AM

#546393 RE: LessIsMore #546346

Stupp is old guard, but wow is the landscape changing in medicine.

For example....my old ortho surgeon told me STEM cell/PRP injections wouldn't work on my shoulder torn labrum and rotor cuff...my new surgeon, about 20 years younger and much more open minding and trained/schooled in the new guard of Ortho Surgery, said it would. I dished out the cash myself and had it done. 1 year later my shoulder is as good as new and hasn't felt this good since I was 18. Its battle tested" This past year was the first year I haven't been in pain while fighting fires and working out. About 150 workouts and 40 something fires later. If you have a old Doctor, even a PCP, who is old, replace him/her with someone younger. Its a night and day difference in the care you will receive.

Time are changing, both in how Othro Surgeons think/work and how the FDA will look at ECA's in some of the deadly diseases. With much smaller powered trials too.

-Fireman
icon url

ilovetech

12/09/22 11:28 AM

#546415 RE: LessIsMore #546346

Less - I disagree with this practice of publishing a paper at so late a stage in the development cycle of a potential introduction of a new treatment. There are too many practical reasons, but here's what immediately comes to mind: An appearance of conflict, reliance on views that are seen as less predictive in light of new understandings. it can lead to confusion, especially among those less sophisticated. It shifts attention wittingly or unwittingly away from newer scientific knowledge the treatment has brought to light. It fails to address the mechanisms and their effects at a molecular level to explain the rationale behind improved outcomes either on its own, or as an adjunct for further improvement. Or conversely, why the approach fails to support better outcomes.

I have noticed the identical B.S. playbook used by the the same "kind" of cadre of naysayers in other biotechs, who can't find their way out of a box of their own self-serving misguided making.

ILT